Autoimmune destruction of small intrahepatic bile ducts → cholestasis, pruritus, fatigue; AMA-positive in 95%.
Try two board-style Primary Biliary Cholangitis questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1GastrointestinalMedium
A 62-year-old woman with primary biliary cholangitis has been taking ursodeoxycholic acid for 2 years, with normalization of her alkaline phosphatase and bilirubin. She has no cirrhosis. Which of the following is the most important long-term monitoring step?
- AAnnual variceal screening endoscopy
- BRepeat antimitochondrial antibody titers
- CSemiannual abdominal CT
- DBone density (DEXA) screening
Reveal answer & full explanation
Correct answer: D — Bone density (DEXA) screening
- AAnnual variceal screening endoscopy
- BRepeat antimitochondrial antibody titers
- CSemiannual abdominal CT
- DBone density (DEXA) screening✓
Why Bone density (DEXA) screening is correct
- Chronic cholestasis in primary biliary cholangitis impairs absorption of vitamin D and calcium, so osteoporosis is a common complication in all patients regardless of disease stage or biochemical response
- Guidelines recommend a baseline DEXA scan with periodic reassessment, plus calcium and vitamin D supplementation, as standard long-term care in primary biliary cholangitis
- A good biochemical response to ursodeoxycholic acid lowers progression risk but does not remove the ongoing metabolic bone risk, so monitoring still matters
Why the others are wrong
- Annual variceal screening endoscopy — Endoscopic variceal surveillance is indicated only once cirrhosis or portal hypertension is established, and this patient has neither (anchoring on chronic liver disease as automatically requiring endoscopy)
- Repeat antimitochondrial antibody titers — Antimitochondrial antibody establishes the diagnosis, but its titer does not track disease activity, treatment response, or complications, so serial testing changes no management (confusing a diagnostic marker with a monitoring tool)
- Semiannual abdominal CT — There is no role for routine surveillance CT; HCC surveillance, only once cirrhosis is present, is done with ultrasound every 6 months, not CT (confused with the HCC surveillance modality)
Question 2GastrointestinalMedium
A 52-year-old woman presents with 6 months of progressive fatigue and intermittent nocturnal itching. She has a history of Sjögren syndrome. Examination shows excoriations on the forearms and mild hepatomegaly; there is no jaundice or ascites. Laboratory studies show alkaline phosphatase 410 U/L (3× ULN) and GGT 280 U/L, with AST 38 U/L and ALT 42 U/L and a normal total bilirubin. Antimitochondrial antibody is positive at 1:160, and IgM is elevated. Abdominal ultrasound shows no biliary dilation, and MRCP is normal. Which of the following is the most appropriate initial management?
- APrednisone immunosuppression
- BOral ursodeoxycholic acid
- CObeticholic acid monotherapy
- DCholestyramine resin therapy
Reveal answer & full explanation
Correct answer: B — Oral ursodeoxycholic acid
- APrednisone immunosuppression
- BOral ursodeoxycholic acid✓
- CObeticholic acid monotherapy
- DCholestyramine resin therapy
Why Oral ursodeoxycholic acid is correct
- This is classic primary biliary cholangitis: a middle-aged woman with fatigue, pruritus, a cholestatic biochemistry (alkaline phosphatase and GGT disproportionately elevated relative to AST/ALT), positive AMA, and elevated IgM.
- Per AASLD/EASL guidelines, ursodeoxycholic acid 13-15 mg/kg/day is first-line for ALL patients with PBC and is the only therapy proven to improve transplant-free survival. Biochemical response is reassessed at 12 months (Paris II / Toronto criteria).
Why the others are wrong
- Obeticholic acid is an FXR agonist used as second-line therapy only for patients with an inadequate response to or intolerance of UDCA; it is not started up front and carries an FDA boxed warning against use in decompensated cirrhosis.
- Cholestyramine is a bile acid sequestrant that treats the symptom of pruritus but does not alter disease progression; it must also be separated from UDCA by at least 4 hours and is adjunctive rather than initial disease-modifying therapy.
- Prednisone (corticosteroids) is the treatment for autoimmune hepatitis, which shows a hepatocellular (AST/ALT-predominant) pattern with ANA/ASMA and elevated IgG; it is not effective for PBC and adds osteoporosis risk in an already high-risk population.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Primary Biliary Cholangitis (PBC) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Free to start · No credit card · Cancel anytime
Risk factors
- Female sex, age 40-60
- Family history of PBC or other autoimmune disease
- Smoking
- Recurrent urinary tract infections
- Environmental exposures (xenobiotics, hair dye)
Pathophysiology
Autoimmune injury (T-cell mediated with autoantibody markers — antimitochondrial antibodies (AMA) against the E2 subunit of pyruvate dehydrogenase) targets small bile duct epithelium, producing progressive ductopenia, cholestasis, and bile acid retention with secondary hepatocyte injury, fibrosis, and ultimately cirrhosis.
Clinical presentation
Symptoms
- Often asymptomatic at diagnosis (incidental cholestatic LFT pattern in ~60%)
- Fatigue (the most common symptom, often disabling)
- Pruritus (often nocturnal, worsens before jaundice)
- Right upper quadrant discomfort
- Sicca symptoms (dry eyes, dry mouth)
- Late: jaundice, hepatosplenomegaly, ascites, variceal bleeding (with cirrhosis)
Signs / physical exam
- Hyperpigmentation, xanthelasmas, xanthomas (from prolonged cholestasis and hyperlipidemia)
- Hepatomegaly, splenomegaly
- Excoriations from scratching
- Findings of associated autoimmune disease (Sjögren, thyroid, RA)
- Late: jaundice, ascites, asterixis
Classic findings
Middle-aged woman with fatigue, pruritus, and isolated alkaline phosphatase elevation — check AMA.
Differential diagnosis
- Primary sclerosing cholangitis — Cholestatic pattern with intrahepatic AND extrahepatic bile duct strictures on MRCP; strong IBD association; ANCA may be positive; AMA usually negative
- Autoimmune hepatitis — Hepatocellular (AST/ALT) > cholestatic pattern, ANA/ASMA positive, IgG elevation, interface hepatitis on biopsy
- Drug-induced cholestasis — Temporal relation to medication (amoxicillin-clavulanate, anabolic steroids, OCPs); resolves with withdrawal
- Extrahepatic biliary obstruction (stones, malignancy, stricture) — Dilated extrahepatic ducts on imaging; ERCP/MRCP confirms
- Sarcoidosis with hepatic involvement — Granulomas, pulmonary findings, hypercalcemia, ACE elevation
- IgG4-related sclerosing cholangitis — Elevated IgG4, characteristic imaging, response to corticosteroids
Diagnostic workup
Diagnostic criteria
2 of 3: (1) cholestatic biochemistry (elevated alkaline phosphatase ≥1.5× ULN >6 months), (2) AMA positive (≥1:40) or PBC-specific ANA, (3) liver biopsy showing nonsuppurative destructive cholangitis with bile duct injury. Biopsy not required if first two are met.
Labs
- LFTs — cholestatic pattern: elevated alkaline phosphatase and GGT, normal-to-modestly elevated AST/ALT, normal bilirubin early
- Antimitochondrial antibody (AMA) — positive in ~95%; highly specific
- If AMA negative: AMA-negative PBC variants — anti-sp100, anti-gp210 (PBC-specific ANA patterns)
- IgM (elevated), total IgG (less elevated than AIH)
- Lipid panel (often markedly elevated cholesterol; not strongly atherogenic in PBC)
- TSH (for coexistent autoimmune thyroiditis), celiac serology if symptoms
- Fat-soluble vitamins (A, D, E, K) — deficiency in advanced cholestasis
- Bone density (DEXA) — high osteoporosis risk
Imaging
- Abdominal ultrasound — exclude biliary obstruction; nonspecific for PBC
- MRCP — typically normal in PBC (distinguishes from PSC, which shows beading)
Treatment
First-line
- Ursodeoxycholic acid (UDCA) 13-15 mg/kg/day in divided doses — first-line for all PBC patients; improves transplant-free survival
- Assess biochemical response at 12 months: Paris II / Toronto criteria — alkaline phosphatase reduction to <1.67× ULN and normal bilirubin
Second-line / adjunct
- Obeticholic acid (FXR agonist) 5-10 mg/day — for incomplete UDCA response or intolerance; avoid in advanced cirrhosis (Child B/C, portal hypertension) due to hepatic decompensation risk
- Fibrates (bezafibrate, fenofibrate) — off-label; improve biochemistry in incomplete UDCA responders
- Symptomatic pruritus: cholestyramine (separate from UDCA by ≥4 h), rifampin, naltrexone, sertraline; light therapy and antihistamines adjunctive
- Liver transplantation for end-stage disease or refractory pruritus — excellent outcomes; PBC can recur in graft
Complications
- Cirrhosis with portal hypertension, varices, ascites, encephalopathy
- Hepatocellular carcinoma (lower risk than hepatitis B/C; higher in men with PBC)
- Osteoporosis with fractures
- Hyperlipidemia (paradoxically not strongly associated with atherosclerotic disease)
- Fat-soluble vitamin deficiencies (night blindness, osteomalacia, neuropathy, coagulopathy)
- Severe refractory pruritus
PANCE pearls
- Middle-aged woman + fatigue + pruritus + isolated alk phos elevation → check AMA.
- Cholestatic pattern: alk phos disproportionately elevated relative to AST/ALT. GGT confirms hepatic origin.
- UDCA is the only therapy proven to improve transplant-free survival in PBC — start in all patients.
- Obeticholic acid is now contraindicated in patients with PBC and decompensated cirrhosis (FDA boxed warning).
- PBC has the highest osteoporosis risk of any chronic liver disease — DEXA every 2 years, calcium and vitamin D for all.
References
- AASLD 2018 — AASLD Practice Guidance: Primary Biliary Cholangitis (Lindor et al., Hepatology 2019)
- EASL 2017 — EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis (J Hepatol 2017)
- ACG 2018 — ACG Clinical Guideline: Primary Sclerosing Cholangitis and Primary Biliary Cholangitis (Bowlus et al., 2023 update)